Psybiome investigates how the gut microbiome regulates the body's response to psychedelics, determining how gut health impacts the intensity and quality of the experience. Through clinical-grade sequencing and dietary trials, the study identifies specific protocols that biologically "prime" the body for optimized therapeutic outcomes and faster recovery. This research generates a proprietary foundational dataset used to build commercial nutrition kits and predictive safety tools for the psychedelic industry.
Andrew Quigley
Research Lead